Shannon M Bates1, Ian A Greer2, Saskia Middeldorp3, David L Veenstra4, Anne-Marie Prabulos5, Per Olav Vandvik6. 1. Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada. Electronic address: batesm@mcmaster.ca. 2. Faculty of Health and Life Sciences, University of Liverpool, Liverpool, England. 3. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. 4. Department of Pharmacy, University of Washington, Seattle, WA. 5. Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT. 6. Medical Department, Innlandet Hospital Trust and Norwegian Knowledge Centre for the Health Services, Gjøvik, Norway.
Abstract
BACKGROUND: The use of anticoagulant therapy during pregnancy is challenging because of the potential for both fetal and maternal complications. This guideline focuses on the management of VTE and thrombophilia as well as the use of antithrombotic agents during pregnancy. METHODS: The methods of this guideline follow the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. RESULTS: We recommend low-molecular-weight heparin for the prevention and treatment of VTE in pregnant women instead of unfractionated heparin (Grade 1B). For pregnant women with acute VTE, we suggest that anticoagulants be continued for at least 6 weeks postpartum (for a minimum duration of therapy of 3 months) compared with shorter durations of treatment (Grade 2C). For women who fulfill the laboratory criteria for antiphospholipid antibody (APLA) syndrome and meet the clinical APLA criteria based on a history of three or more pregnancy losses, we recommend antepartum administration of prophylactic or intermediate-dose unfractionated heparin or prophylactic low-molecular-weight heparin combined with low-dose aspirin (75-100 mg/d) over no treatment (Grade 1B). For women with inherited thrombophilia and a history of pregnancy complications, we suggest not to use antithrombotic prophylaxis (Grade 2C). For women with two or more miscarriages but without APLA or thrombophilia, we recommend against antithrombotic prophylaxis (Grade 1B). CONCLUSIONS: Most recommendations in this guideline are based on observational studies and extrapolation from other populations. There is an urgent need for appropriately designed studies in this population.
BACKGROUND: The use of anticoagulant therapy during pregnancy is challenging because of the potential for both fetal and maternal complications. This guideline focuses on the management of VTE and thrombophilia as well as the use of antithrombotic agents during pregnancy. METHODS: The methods of this guideline follow the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. RESULTS: We recommend low-molecular-weight heparin for the prevention and treatment of VTE in pregnant women instead of unfractionated heparin (Grade 1B). For pregnant women with acute VTE, we suggest that anticoagulants be continued for at least 6 weeks postpartum (for a minimum duration of therapy of 3 months) compared with shorter durations of treatment (Grade 2C). For women who fulfill the laboratory criteria for antiphospholipid antibody (APLA) syndrome and meet the clinical APLA criteria based on a history of three or more pregnancy losses, we recommend antepartum administration of prophylactic or intermediate-dose unfractionated heparin or prophylactic low-molecular-weight heparin combined with low-dose aspirin (75-100 mg/d) over no treatment (Grade 1B). For women with inherited thrombophilia and a history of pregnancy complications, we suggest not to use antithrombotic prophylaxis (Grade 2C). For women with two or more miscarriages but without APLA or thrombophilia, we recommend against antithrombotic prophylaxis (Grade 1B). CONCLUSIONS: Most recommendations in this guideline are based on observational studies and extrapolation from other populations. There is an urgent need for appropriately designed studies in this population.
Authors: Winnie W Sia; Raymond O Powrie; Ann B Cooper; Lucia Larson; Maureen Phipps; Patricia Spencer; Nadine Sauve; Karen Rosene-Montella Journal: Thromb Res Date: 2008-08-15 Impact factor: 3.944
Authors: H Qublan; Z Amarin; M Dabbas; A-E Farraj; Z Beni-Merei; H Al-Akash; A-N Bdoor; M Nawasreh; S Malkawi; F Diab; N Al-Ahmad; M Balawneh; A Abu-Salim Journal: Hum Fertil (Camb) Date: 2008-12 Impact factor: 2.767
Authors: E Rey; P Garneau; M David; R Gauthier; L Leduc; N Michon; F Morin; C Demers; S R Kahn; L A Magee; M Rodger Journal: J Thromb Haemost Date: 2008-11-20 Impact factor: 5.824
Authors: M Heather Einstein; David M Kushner; Joseph P Connor; Alex A Bohl; Thomas J Best; Michael D Evans; Richard J Chappell; Ellen M Hartenbach Journal: Obstet Gynecol Date: 2008-11 Impact factor: 7.661
Authors: Alyshah Abdul Sultan; Matthew J Grainge; Joe West; Kate M Fleming; Catherine Nelson-Piercy; Laila J Tata Journal: Blood Date: 2014-08-25 Impact factor: 22.113
Authors: Hooman Kamel; Babak B Navi; Nandita Sriram; Dominic A Hovsepian; Richard B Devereux; Mitchell S V Elkind Journal: N Engl J Med Date: 2014-02-13 Impact factor: 91.245
Authors: Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg Journal: Blood Adv Date: 2018-11-27